Latest News

As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock...

In recent commentary, Viavi Solutions has been highlighted as a key optics industry player, supplying critical test equipment that underpins reliable high-speed optical connectivity across the supply chain. The emphasis on Viavi’s essential role in validating 400G, 800G and 1.6T optics before deployment underscores its potential importance to long-term infrastructure upgrades and broader industry resilience. We’ll now examine how Viavi’s reinforced role in high-speed optics testing could...

Sichuan Kelun-Biotech Biopharmaceutical has called an extraordinary general meeting for 31 December 2025 to approve several 2026 framework agreements covering promotional services, auxiliary R&D support, and procurement and sale of equipment and materials, while also settling trade secret and civil litigation disputes with MediLink Therapeutics through a profit- and income-sharing arrangement. By simultaneously formalising future operating relationships and removing legal uncertainty via the...

Earlier this week, Brightstar Lottery PLC announced that its subsidiaries signed a 19-year contract with Lotterywest to supply a new central gaming system, 775 retailer terminals, and a full digital offering for Western Australia’s lottery operations. Beyond the technology win, Brightstar committed to long-term local job creation, university scholarships, and broader digital capability-building in Western Australia, deepening its role as an embedded partner rather than just an infrastructure...

Kanzhun (NasdaqGS:BZ) just reshuffled its leadership bench, moving long time finance chief Phil Yu Zhang into a new Chief Strategy Officer role while elevating Yang Mu and Wenbei Wang into boardroom and finance positions. See our latest analysis for Kanzhun. The shake up comes after a strong run for the stock, with the latest share price at $20.82 and a robust year to date share price return of 52.64 percent. This suggests momentum is still building even after a softer 90 day share price...

Coloplast has recently announced upcoming changes to its Executive Leadership Team, with long-serving leaders in People & Culture and Interventional Urology set to depart and successors, including incoming Interventional Urology head Kevin Hardage from Teleflex, lined up to ensure business continuity. These leadership shifts, particularly in the Interventional Urology division and the global People & Culture function, could influence how effectively Coloplast executes its reorganisation,...

Praxis Precision Medicines (PRAX) just cleared a key regulatory hurdle, wrapping up a Type C meeting with the FDA that reshapes its EMBRAVE3 trial for elsunersen into a leaner single arm design. See our latest analysis for Praxis Precision Medicines. The news around EMBRAVE3 lands on top of a powerful run, with Praxis delivering a roughly 44 percent 1 month share price return and a staggering 546 percent 3 month share price return, while its 1 year total shareholder return above 250 percent...

A fresh class action lawsuit has put F5 (FFIV) back in the spotlight, accusing the company of downplaying a major security breach tied to its flagship BIG-IP product and reshaping the stock’s risk profile. See our latest analysis for F5. The lawsuit caps a volatile stretch for F5, where a sharp post earnings sell off and insider share sales have kept sentiment fragile, even as product launches and AI focused partnerships hint at longer term growth optionality. While the latest share price...

In December 2025, United Natural Foods, Inc. filed a US$49.70 million shelf registration for 1,500,000 common shares tied to an ESOP-related offering and, at its Investor Day, highlighted technology-enabled ecommerce growth, AI-driven supply chain tools, and resumed stock buybacks as it pursues low-single digit sales growth and low-double digit EBITDA growth through fiscal 2028. By pairing leaner distribution center operations with an expanded retail media network and advanced digital...

K92 Mining (TSX:KNT) is pushing ahead with its Stage 3 Expansion at the Kainantu Mine, ramping up production capacity, upgrading infrastructure, and rolling out advanced processing technology to support a longer term growth profile. See our latest analysis for K92 Mining. The market seems to be recognising that this expansion is not just a capacity bump but a step change in scale. A powerful year to date share price return of 157.46 percent and a three year total shareholder return of 197.55...

Hygeia Healthcare Holdings Co., Limited (SEHK:6078) has begun repurchasing its own shares under a shareholder-approved mandate allowing buybacks of up to 61,849,900 shares, alongside a separate program of up to CNY 300,000,000 announced on December 15, 2025. The twin authorizations, representing as much as 10% of issued share capital, highlight management’s focus on boosting net assets and earnings per share through capital management. We’ll now examine how this sizeable buyback...

Hilton Grand Vacations (HGV) just closed a $400 million securitization of its timeshare loans, a sizable financing move that boosts liquidity and gives investors fresh insight into the company’s funding costs and credit profile. See our latest analysis for Hilton Grand Vacations. The securitization lands at a moment when sentiment around Hilton Grand Vacations is perking up, with the share price at $45.34 after a strong 1 month share price return of 21.26 percent and an 18.23 percent year to...

Natera recently reported that the phase III CALGB (Alliance)/SWOG 80702 trial, now published in JAMA Oncology, showed that adding celecoxib to FOLFOX chemotherapy after surgery reduced recurrence and death risk in Signatera-positive stage III colorectal cancer patients, while multiple new breast cancer studies further reinforced the prognostic power of its Signatera ctDNA assays. Together with a fresh MiRaDoR collaboration in hormone receptor-positive breast cancer and updated PALLAS MRD...

Earlier in 2025, CBL & Associates Properties announced a new US$25 million stock repurchase program through November 2026 and closed nearly US$158 million in financing across three transactions, including a lower-rate US$43 million loan used to retire existing debt. These moves highlight the company’s focus on capital allocation and refinancing to potentially strengthen its balance sheet and operational flexibility. Next, we’ll examine how the new US$25 million buyback program could...

Key Insights Significant control over Ackermans & Van Haaren by individual investors implies that the general public...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

learnd SE ( FRA:LRND ) shares have retraced a considerable 28% in the last month, reversing a fair amount of their...

Avantor recently announced that Simon Dingemans, a veteran executive with senior roles at GSK, Goldman Sachs and Carlyle, will join its Board of Directors effective January 2, 2026. This appointment brings additional healthcare, finance and corporate governance expertise to Avantor at a time when its competitive positioning and disclosures are under scrutiny from multiple securities class action lawsuits. We’ll now examine how the addition of Simon Dingemans to Avantor’s board shapes the...

Canadian Solar’s e-STORAGE division recently agreed to supply a 204 MW / 408 MWh battery energy storage system to Vena Energy’s Tailem Bend 3 project in South Australia, which is scheduled to begin operating in 2027 under an initial five-year service and maintenance agreement. This contract marks e-STORAGE’s fourth major battery project in Australia, lifting its installed and contracted footprint in the country to about 2 GWh and underscoring the company’s growing role in grid stability and...

Tyson Foods (TSN) has quietly outperformed the broader meat sector over the past month, climbing about 10% as investors warm up to improving earnings trends and steadier demand across beef, pork, and chicken. See our latest analysis for Tyson Foods. Zooming out, that recent 10.2% 1 month share price return has only nudged Tyson Foods to a modest 4.4% 1 year total shareholder return. Investors are still treating the latest operational improvements as early stage momentum rather than a full re...

Recently, Alaska Air Group lowered its fourth-quarter earnings outlook amid operational headwinds, while also announcing new 2026 route additions from Anchorage, Portland, and Seattle Paine Field that broaden its domestic and long-haul international network. Alongside these network moves, the company is investing in Hawai'i-produced sustainable aviation fuel and elevating safety leadership, signaling a focus on long-term efficiency and risk management even as near-term profit expectations...

Earlier this year, Getty Realty Corp. reported stronger-than-expected quarterly results, raising its AFFO guidance while maintaining portfolio occupancy at 99.8% and highlighting an almost 7% dividend yield. The combination of higher cash-flow guidance, accelerated investment activity, and a balance sheet with low leverage and no major debt due until 2028 underscored the REIT’s income resilience and financial flexibility. We’ll now explore how Getty’s raised AFFO guidance and stronger...

Wondering if Astellas Pharma’s strong run still offers value, or if you might be late to the party? This breakdown will help you decide whether the current price still makes sense. The stock has climbed 2.2% over the last week, 9.7% in the past month, and is up 37.5% year to date and 43.0% over the last year, so it is firmly on many investors’ radar. Recent headlines have focused on Astellas expanding its pipeline through strategic partnerships and regulatory milestones for key therapies,...

Peloton Interactive recently posted quarterly results showing a 6% year-on-year revenue decline but beating market expectations on revenue, EPS, and adjusted operating income, while management emphasized disciplined execution ahead of new product launches like Peloton IQ. Despite this operational progress, analysts have responded cautiously, with several reiterating Hold or Neutral ratings as they factor in higher churn, softer full-year guidance, and ongoing retail sector challenges. We’ll...